Shengqing Jiangzhuo Capsule Alleviates Intestinal Inflammation in Chronic Kidney Disease by Downregulating CHAC1 to Inactivate the HIF‐1 Pathway
SQJZ alleviates intestinal inflammation in CKD, potentially mediated by downregulation of CHAC1 and subsequent inactivation of the HIF-1 pathway, positioning SQJZ as a promising gut-targeted therapy in CKD.
Authors
- Liangyou Zhang
- Yuankai Lin (ORCID: https://orcid.org/0000-0002-1176-4669)
- Xingbo Wu (ORCID: https://orcid.org/0000-0003-0452-4373)
- Zhibin Li (ORCID: https://orcid.org/0000-0001-6642-9780)
- Chao Wang (ORCID: https://orcid.org/0000-0002-0900-5794)
- Shu Zhang (ORCID: https://orcid.org/0000-0001-8470-9727)
- Jiannong Wang (ORCID: https://orcid.org/0000-0002-6133-6371)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- First Affiliated Hospital of Sichuan Medical University (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Mediators of Inflammation
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/mi/2173234
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Traditional Chinese Medicine Bureau of Guangdong Province